Amgen Inc. $AMGN Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 655,511 shares of the medical research company’s stock after selling 4,482 shares during the quarter. Amgen comprises about 2.2% of Sarasin & Partners LLP’s holdings, making the stock its 18th largest position. Sarasin & Partners LLP owned approximately 0.12% of Amgen worth $214,555,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Board of the Pension Protection Fund purchased a new position in shares of Amgen in the 4th quarter valued at approximately $26,000. Evelyn Partners Investment Management LLP acquired a new position in shares of Amgen in the second quarter valued at approximately $32,000. Holos Integrated Wealth LLC purchased a new stake in shares of Amgen during the fourth quarter worth approximately $37,000. Howard Hughes Medical Institute purchased a new stake in shares of Amgen during the second quarter worth approximately $32,000. Finally, Cloud Capital Management LLC acquired a new stake in shares of Amgen during the third quarter worth $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $347.80 on Friday. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The business has a fifty day moving average of $360.29 and a two-hundred day moving average of $327.80. The company has a market cap of $187.49 billion, a P/E ratio of 24.44, a price-to-earnings-growth ratio of 3.45 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the prior year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Analyst Upgrades and Downgrades

AMGN has been the topic of several recent research reports. HSBC reissued a “buy” rating and issued a $425.00 price objective on shares of Amgen in a research note on Wednesday, December 10th. Leerink Partners restated a “market perform” rating and issued a $355.00 target price on shares of Amgen in a research note on Thursday, March 5th. BMO Capital Markets lifted their target price on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. Truist Financial boosted their price target on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. Finally, Jefferies Financial Group initiated coverage on shares of Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus price target of $354.60.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.